Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.59
- Piotroski Score 3.00
- Grade Buy
- Symbol (OCUL)
- Company Ocular Therapeutix, Inc.
- Price $8.77
- Changes Percentage (-1.74%)
- Change -$0.16
- Day Low $8.57
- Day High $8.99
- Year High $11.78
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $24.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.12
- Trailing P/E Ratio -4.41
- Forward P/E Ratio -4.41
- P/E Growth -4.41
- Net Income $-80,736,000
Income Statement
Quarterly
Annual
Latest News of OCUL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Exclusive | Creepy NYC construction workers film, use binoculars to spy on female...
Construction workers at Hudson Yards are accused of lewd behavior, peeping at female students and residents through windows. The incidents have sparked outrage and concern, prompting responses from au...
By New York Post | 5 days ago -
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...
Cash and cash equivalents stood at around $427 million by the end of the third quarter. The company discusses the overlap of sites for SO1 and Solar studies, aiming for a differentiated product label ...
By Yahoo! Finance | 6 days ago -
Opinion | I Don't Want to Live in a Monoculture, and Neither Do You
The author reflects on the failures of diversity programs at the University of Michigan and the dangers of ideological monocultures in both left and right-wing institutions. Intellectual diversity and...
By The New York Times | 1 month ago
